Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel
AbstractBackground Glioblastoma (GBM) is a primary malignancy of the central nervous system and is classified as a grade IV astrocytoma by the World Health Organization (WHO). Although GBM rarely metastasizes, its prognosis remains poor. Moreover, the standard treatment for GBM, temozolomide (TMZ),...
| Asıl Yazarlar: | , , , , , , , , , , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
Taylor & Francis Group
2023-12-01
|
| Seri Bilgileri: | Annals of Medicine |
| Konular: | |
| Online Erişim: | https://www.tandfonline.com/doi/10.1080/07853890.2024.2305308 |
| _version_ | 1827346531524542464 |
|---|---|
| author | Munazza Ahmed Ahlam M. Semreen Alexander D. Giddey Wafaa S. Ramadan Raafat El-Awady Nelson C. Soares Waseem El-Huneidi Yasser Bustanji Mohammad A. Y. Alqudah Karem H. Alzoubi Mohammad H. Semreen |
| author_facet | Munazza Ahmed Ahlam M. Semreen Alexander D. Giddey Wafaa S. Ramadan Raafat El-Awady Nelson C. Soares Waseem El-Huneidi Yasser Bustanji Mohammad A. Y. Alqudah Karem H. Alzoubi Mohammad H. Semreen |
| author_sort | Munazza Ahmed |
| collection | DOAJ |
| description | AbstractBackground Glioblastoma (GBM) is a primary malignancy of the central nervous system and is classified as a grade IV astrocytoma by the World Health Organization (WHO). Although GBM rarely metastasizes, its prognosis remains poor. Moreover, the standard treatment for GBM, temozolomide (TMZ), is associated with chemoresistance, which is a major factor behind GBM-related deaths. Investigating drugs with repurposing potential in the context of GBM is worthwhile to bypass lengthy bench-to-bedside research. The field of omics has garnered significant interest in scientific research because of its potential to delineate the intricate regulatory network underlying tumor development. In particular, proteomic and metabolomic analyses are powerful approaches for the investigation of metabolic enzymes and intermediate metabolites since they represent the functional end of the cancer phenotype.Methods We chose two of the most widely prescribed anticancer drugs, cisplatin and paclitaxel. To our knowledge, the current literature lacks studies examining their effects on metabolic and proteomic alterations in GBM. We employed the mass spectrometry technological platform ‘UHPLC-Q-TOF-MS/MS’ to examine the changes in the proteome and metabolome profiles of the U87 cell line with defined concentrations of cisplatin and/or paclitaxel via an untargeted approach.Results A total of 1,419 distinct proteins and 90 metabolites were generated, and subsequent analysis was performed. We observed that upon treatment with cisplatin (9.5 μM), U87 cells exhibited apparent efforts to cope with this exogenous stressor, understanding the effect of paclitaxel (5.3 μM) on altering the transport machinery of the cell, and how the combination of cisplatin and/or paclitaxel suggests potential interactions with promising benefits in GBM therapeutics.Conclusion Our research provides a detailed map of alterations in response to cisplatin and paclitaxel treatment, provides crucial insights into the molecular basis of their action, and paves the way for further research to identify molecular targets for this elusive malignancy. |
| first_indexed | 2024-03-07T23:32:29Z |
| format | Article |
| id | doaj.art-4f3c0d78de8d438a842559c6914ff1b1 |
| institution | Directory Open Access Journal |
| issn | 0785-3890 1365-2060 |
| language | English |
| last_indexed | 2024-03-07T23:32:29Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj.art-4f3c0d78de8d438a842559c6914ff1b12024-02-20T11:58:25ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602023-12-0155210.1080/07853890.2024.2305308Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxelMunazza Ahmed0Ahlam M. Semreen1Alexander D. Giddey2Wafaa S. Ramadan3Raafat El-Awady4Nelson C. Soares5Waseem El-Huneidi6Yasser Bustanji7Mohammad A. Y. Alqudah8Karem H. Alzoubi9Mohammad H. Semreen10Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab EmiratesDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab EmiratesResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab EmiratesResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab EmiratesDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab EmiratesResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab EmiratesResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab EmiratesDepartment of Basic and Clinical Pharmacology, College of Medicine, University of Sharjah, Sharjah, United Arab EmiratesDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab EmiratesDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab EmiratesResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab EmiratesAbstractBackground Glioblastoma (GBM) is a primary malignancy of the central nervous system and is classified as a grade IV astrocytoma by the World Health Organization (WHO). Although GBM rarely metastasizes, its prognosis remains poor. Moreover, the standard treatment for GBM, temozolomide (TMZ), is associated with chemoresistance, which is a major factor behind GBM-related deaths. Investigating drugs with repurposing potential in the context of GBM is worthwhile to bypass lengthy bench-to-bedside research. The field of omics has garnered significant interest in scientific research because of its potential to delineate the intricate regulatory network underlying tumor development. In particular, proteomic and metabolomic analyses are powerful approaches for the investigation of metabolic enzymes and intermediate metabolites since they represent the functional end of the cancer phenotype.Methods We chose two of the most widely prescribed anticancer drugs, cisplatin and paclitaxel. To our knowledge, the current literature lacks studies examining their effects on metabolic and proteomic alterations in GBM. We employed the mass spectrometry technological platform ‘UHPLC-Q-TOF-MS/MS’ to examine the changes in the proteome and metabolome profiles of the U87 cell line with defined concentrations of cisplatin and/or paclitaxel via an untargeted approach.Results A total of 1,419 distinct proteins and 90 metabolites were generated, and subsequent analysis was performed. We observed that upon treatment with cisplatin (9.5 μM), U87 cells exhibited apparent efforts to cope with this exogenous stressor, understanding the effect of paclitaxel (5.3 μM) on altering the transport machinery of the cell, and how the combination of cisplatin and/or paclitaxel suggests potential interactions with promising benefits in GBM therapeutics.Conclusion Our research provides a detailed map of alterations in response to cisplatin and paclitaxel treatment, provides crucial insights into the molecular basis of their action, and paves the way for further research to identify molecular targets for this elusive malignancy.https://www.tandfonline.com/doi/10.1080/07853890.2024.2305308CisplatinglioblastomaGBMpaclitaxelproteomicssystems biology |
| spellingShingle | Munazza Ahmed Ahlam M. Semreen Alexander D. Giddey Wafaa S. Ramadan Raafat El-Awady Nelson C. Soares Waseem El-Huneidi Yasser Bustanji Mohammad A. Y. Alqudah Karem H. Alzoubi Mohammad H. Semreen Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel Annals of Medicine Cisplatin glioblastoma GBM paclitaxel proteomics systems biology |
| title | Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel |
| title_full | Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel |
| title_fullStr | Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel |
| title_full_unstemmed | Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel |
| title_short | Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel |
| title_sort | proteomic and metabolomic signatures of u87 glioblastoma cells treated with cisplatin and or paclitaxel |
| topic | Cisplatin glioblastoma GBM paclitaxel proteomics systems biology |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2024.2305308 |
| work_keys_str_mv | AT munazzaahmed proteomicandmetabolomicsignaturesofu87glioblastomacellstreatedwithcisplatinandorpaclitaxel AT ahlammsemreen proteomicandmetabolomicsignaturesofu87glioblastomacellstreatedwithcisplatinandorpaclitaxel AT alexanderdgiddey proteomicandmetabolomicsignaturesofu87glioblastomacellstreatedwithcisplatinandorpaclitaxel AT wafaasramadan proteomicandmetabolomicsignaturesofu87glioblastomacellstreatedwithcisplatinandorpaclitaxel AT raafatelawady proteomicandmetabolomicsignaturesofu87glioblastomacellstreatedwithcisplatinandorpaclitaxel AT nelsoncsoares proteomicandmetabolomicsignaturesofu87glioblastomacellstreatedwithcisplatinandorpaclitaxel AT waseemelhuneidi proteomicandmetabolomicsignaturesofu87glioblastomacellstreatedwithcisplatinandorpaclitaxel AT yasserbustanji proteomicandmetabolomicsignaturesofu87glioblastomacellstreatedwithcisplatinandorpaclitaxel AT mohammadayalqudah proteomicandmetabolomicsignaturesofu87glioblastomacellstreatedwithcisplatinandorpaclitaxel AT karemhalzoubi proteomicandmetabolomicsignaturesofu87glioblastomacellstreatedwithcisplatinandorpaclitaxel AT mohammadhsemreen proteomicandmetabolomicsignaturesofu87glioblastomacellstreatedwithcisplatinandorpaclitaxel |